Halozyme Therapeutics, Inc. (LON:0J2O)
London
· Delayed Price · Currency is GBP · Price in USD 57.93
+1.42 (2.52%)
At close: Feb 21, 2025
Halozyme Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 444.09 | 281.59 | 202.13 | 402.71 | 129.09 | Upgrade
|
| Depreciation & Amortization | 78.81 | 84.86 | 49.64 | 3 | 3.28 | Upgrade
|
| Other Amortization | 7.35 | 7.3 | 7.84 | 3.64 | 14.14 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.53 | 0.61 | 0.13 | - | -0.77 | Upgrade
|
| Asset Writedown & Restructuring Costs | 2.5 | - | - | - | 0.58 | Upgrade
|
| Loss (Gain) From Sale of Investments | -10.93 | -6.32 | 2.83 | 2.26 | 0.84 | Upgrade
|
| Stock-Based Compensation | 43.39 | 36.62 | 24.4 | 20.82 | 17.2 | Upgrade
|
| Other Operating Activities | 1.6 | 22.58 | 39.09 | -136.72 | -0.53 | Upgrade
|
| Change in Accounts Receivable | -74.25 | -3.34 | -83.94 | 6.76 | -38.29 | Upgrade
|
| Change in Inventory | -67.38 | -26.88 | -17.48 | 7.37 | -31.39 | Upgrade
|
| Change in Accounts Payable | 46.99 | -12.55 | 24.54 | 1.17 | -41.21 | Upgrade
|
| Change in Other Net Operating Assets | 5.36 | 4.1 | -9.06 | -11.56 | 2.52 | Upgrade
|
| Operating Cash Flow | 479.06 | 388.57 | 240.11 | 299.44 | 55.45 | Upgrade
|
| Operating Cash Flow Growth | 23.29% | 61.83% | -19.81% | 439.98% | - | Upgrade
|
| Capital Expenditures | -10.7 | -15.29 | -4.81 | -1.46 | -2.5 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 26.01 | - | 1.08 | Upgrade
|
| Cash Acquisitions | - | - | -999.12 | - | - | Upgrade
|
| Investment in Securities | -252.03 | -81.62 | 490.92 | -404.83 | 79.78 | Upgrade
|
| Investing Cash Flow | -262.72 | -96.91 | -487.01 | -406.29 | 78.35 | Upgrade
|
| Long-Term Debt Issued | - | - | 1,072 | 784.88 | - | Upgrade
|
| Long-Term Debt Repaid | - | -13.48 | -447.45 | -369.06 | -19.56 | Upgrade
|
| Net Debt Issued (Repaid) | - | -13.48 | 624.55 | 415.81 | -19.56 | Upgrade
|
| Issuance of Common Stock | 31.14 | 7.88 | 14.05 | 12.54 | 63.39 | Upgrade
|
| Repurchase of Common Stock | -250 | -402.38 | -200 | -350.06 | -150.12 | Upgrade
|
| Other Financing Activities | - | - | -76.22 | -0.42 | - | Upgrade
|
| Financing Cash Flow | -218.86 | -407.99 | 362.37 | 77.87 | -106.28 | Upgrade
|
| Net Cash Flow | -2.52 | -116.33 | 115.48 | -28.98 | 27.52 | Upgrade
|
| Free Cash Flow | 468.37 | 373.28 | 235.3 | 297.98 | 52.95 | Upgrade
|
| Free Cash Flow Growth | 25.47% | 58.64% | -21.04% | 462.76% | - | Upgrade
|
| Free Cash Flow Margin | 46.13% | 45.01% | 35.65% | 67.22% | 19.79% | Upgrade
|
| Free Cash Flow Per Share | 3.62 | 2.78 | 1.67 | 2.03 | 0.37 | Upgrade
|
| Cash Interest Paid | 10.57 | 11.41 | 6.11 | 3.3 | 6.53 | Upgrade
|
| Cash Income Tax Paid | 80.62 | 31.76 | 16.22 | -0.38 | 0.18 | Upgrade
|
| Levered Free Cash Flow | 392.93 | 277.24 | 146.42 | 197.82 | 3.92 | Upgrade
|
| Unlevered Free Cash Flow | 396.88 | 281.66 | 149.17 | 198.88 | 2.52 | Upgrade
|
| Change in Net Working Capital | 59.29 | 37.06 | 100.95 | -4.08 | 105.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.